White & Case (New York)

Kevin Adam

White & Case (New York)
Partner

Kevin Adam is a litigation partner in White & Case’s Boston and New York offices and a core member of the Firm’s Global Antitrust/Competition Group. Kevin is a trial lawyer who litigates complex matters at the cutting edge of antitrust and intellectual property, including class actions and competitor lawsuits involving innovation, technology, and pharmaceuticals. He also counsels global clients on a broad range of challenging competition matters, such as pricing practices, licensing and co-development agreements, government investigations, and evolving legislative and regulatory developments. Kevin is a member of the Firm’s Global Pharmaceuticals/Healthcare and Technology Industry Groups and a thought leader on antitrust issues and class actions. He has published more than thirty articles on developments in these areas over the last ten years and co-authored a book on class actions titled "Deconstructing Rule 23: A Comparison of Massachusetts and Federal Class-Action Litigation." In 2021, Kevin was selected to Law360’s Competition Editorial Advisory Board. He is also a member of the ABA Antitrust Section’s Pricing Conduct Committee Advisory Board. Kevin has an extensive pro bono practice, with a focus on criminal appellate work and wrongful convictions. He has represented criminal defendants in federal and state court, successfully overturning a number of convictions in New York’s appellate divisions and securing a jury verdict for a wrongfully convicted man in federal court in Massachusetts. He also works closely with the New England Innocence Project. Kevin graduated from Suffolk University Law School summa cum laude in 2012 and was the Editor-in-Chief of the Suffolk University Law Review. He has also completed executive-level courses in economics at the MIT Sloan School of Management and in global business and negotiation at Harvard Business School. Prior to joining the firm, Kevin worked at the First District Court of Essex County in Salem, Massachusetts and served as a research assistant for the Honorable John M. Greaney, former Associate Justice of the Supreme Judicial Court of Massachusetts.

Distinctions

Linked authors

White & Case (Brussels)
White & Case (Washington)
White & Case (Riyadh)
White & Case (Washington)
White & Case (New York)

Articles

2260 Bulletin

Michael Gallagher, Kristen O’Shaughnessy, Kathryn Jordan Mims, Kevin Adam, Jaclyn Phillips The US President Joe Biden publishes an executive order containing 72 initiatives to address competition concerns in several industries, including pharmaceuticals, biotech, and healthcare

678

Citing concerns about growing consolidation, reduced competition, and increasing prices, President Biden issued on July 9, 2021 a sweeping Executive Order containing 72 initiatives to address competition concerns in a number of industries, including pharmaceuticals, biotech, and healthcare. In (...)

Mark J. Gidley, George Paul, Jack E. Pace, Kathryn Jordan Mims, Kristen O’Shaughnessy, Kevin Adam, Jaclyn Phillips, Abdul Hafiz, Erin McNamee The US President Joe Biden signs an executive order instructing more than a dozen federal agencies to promptly tackle some of the most pressing competition problems across the national economy

547

A new Executive Order signed by President Biden includes 72 initiatives instructing more than a dozen federal agencies, including the US Department of Justice and the Federal Trade Commission, to, according to the White House’s Fact Sheet, "promptly tackle some of the most pressing competition (...)

Mark J. Gidley, Kathryn Jordan Mims, Kristen O’Shaughnessy, Erin McNamee, Kevin Adam, Jaclyn Phillips, Abdul Hafiz, Tal Marnin The US President Joe Biden signs an executive order which includes 72 initiatives aimed at enhancing competition and a directive encouraging the US FTC to ban or limit employee non-compete agreements

176

On Friday, July 9, 2021, President Biden signed Executive Order 14036, Promoting Competition in the American Economy, which includes—among 72 initiatives aimed at enhancing competition in the US—a directive encouraging the Federal Trade Commission to ban or limit employee non-compete agreements. (...)

Noah A. Brumfield, Kevin Adam, Jaclyn Phillips, Chenyuan Fu The US President Joe Biden signs an executive order containing 72 initiatives seeking to coordinate the federal government’s response to what it sees as pressing competition issues and the threat in the rise of large corporations

163

Calls for changes to antitrust law, and how antitrust laws should be applied to the conduct of large technology companies, have been heating up in recent years. Now, the push for wide-scale changes to antitrust law has reached a boiling point. Indeed, President Biden’s sweeping July 9, 2021 (...)

Jack E. Pace, Kristen O’Shaughnessy, Robert Milne, Peter J. Carney, Michael Gallagher, Mark J. Gidley, Kevin Adam The US Congress proposes a package of bills on drug pricing, including changes to the treatment of reverse payments, product hopping, sham petitions, and patent dancing

173

What’s next for drug pricing in the US? Proposals to alter antitrust and patent laws may signal a renewed focus on drug pricing by federal lawmakers, while the growing web of state laws is expected to increase compliance challenges for the pharmaceutical industry. What’s changing? A new (...)

Michael E. Hamburger, Kevin Adam, Abdul Hafiz The US Court of Appeals for the First Circuit holds that no class containing uninjured members can be certified unless, when moving for class certification, plaintiffs offer a manageable way for defendants to contest at trial whether their conduct injured individual class members (In re: Asacol Antitrust Litigation)

122

The U.S. Court of Appeals for the First Circuit’s landmark In re: Asacol Antitrust Litigation decision holds that no class containing uninjured members can be certified unless, when moving for class certification, plaintiffs offer a manageable way for defendants to contest at trial whether their (...)

Send a message